Streetbeat News

Regulatory

FXI

LEGN

Legend Biotech has received approval from the China National Medical Products Administration for its cell therapy product, Ciltacabtagene Autoleucel (Cilta-cel). This approval marks a significant milestone for the company in the Chinese market.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 2:31 pm

RNLX

Renalytix has received an extension from Nasdaq until October 25, 2024, to comply with the minimum bid price and other listing requirements after presenting its operating and financing plan.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 1:44 pm

ILMN

Illumina's TruSight Oncology Comprehensive test receives FDA approval, marking it as the first US FDA-approved genomic profiling IVD kit with pan-cancer companion diagnostic claims. This test can identify biomarkers for targeted cancer therapies, benefiting patients with specific gene fusions.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 1:19 pm

BTCUSD

COIN

ETHUSD

NVDA

PARA

Coinbase is leading a significant donation surge in the blockchain industry for the 2024 election. Bitcoin ETFs have seen a surge in net inflows, while Ethereum ETFs have experienced outflows. The SEC, led by Gary Gensler, is preparing to take action against Kraken, following similar actions against Binance and Coinbase. Nvidia's stock is under scrutiny as traders anticipate its earnings, with a shift from tech stocks to dividend-paying stocks noted. Paramount's shares dipped after a merger deal with Skydance was announced.

Portfolio Pulse from Akanksha Bakshi

August 27, 2024 | 1:18 pm

NITO

N2OFF, Inc. (NASDAQ:NITO) announced that its joint venture with Solterra Renewable Energy has secured approval for its first solar PV project to connect to the power grid in Germany. The project, located in Melz, will have a capacity of 111 MWp.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 1:17 pm

INDV

Indivior PLC has received its first order for the OPVEE nasal spray from the Biomedical Advanced Research and Development Authority (BARDA) to address fentanyl overdoses. This order, funded by Project BioShield, aims to enhance emergency response capabilities in the U.S. against synthetic opioid overdoses.

Portfolio Pulse from Nina Zdinjak

August 27, 2024 | 1:02 pm

ADXN

INDV

JNJ

Addex Therapeutics and Indivior have selected a compound for substance use disorder treatment, with Addex eligible for up to $330 million in milestone payments. Addex will also advance its own compound for chronic cough. Previously, Janssen Pharmaceuticals, a Johnson & Johnson unit, discontinued a compound for epilepsy.

Portfolio Pulse from Vandana Singh

August 27, 2024 | 12:48 pm

ZLAB

Zai Lab Limited will present preliminary data from its Phase 1 trial of ZL-1218, an anti-CCR8 antibody, at the ESMO Congress 2024. The study focuses on the treatment of advanced solid tumors and highlights the potential of ZL-1218 to modulate the tumor microenvironment and regulate anticancer immune response.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:41 pm

META

Mark Zuckerberg, CEO of Meta Platforms, revealed that the Biden administration pressured Meta to censor certain COVID-19 content. Zuckerberg expressed regret for not resisting sooner and vowed to resist future pressures. He also stated he will not support election infrastructure in the upcoming election, marking a shift from 2020.

Portfolio Pulse from Vandana Singh

August 27, 2024 | 12:38 pm

META

Mark Zuckerberg, CEO of Meta, expressed regret over the company's decision to censor content under pressure from the Biden administration. He admitted it was a mistake, particularly in handling the Hunter Biden story, and vowed to resist future interference.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:37 pm